Understanding Differentiated Thyroid Carcinoma: A Comprehensive Guide to Modern Diagnosis, Staging, and Treatment

Table of Contents

• Key Points
• Background: Why This Research Matters
• What Is Differentiated Thyroid Carcinoma?
• How DTC Is Diagnosed: Modern Approaches
• The NIFTP Reclassification: Removing "Cancer" From Select Diagnoses
• Initial and Ongoing Staging: Predicting Risk and Tailoring Care
• Treatment Strategies: From Surgery to Radioactive Iodine
• A Less Extensive Surgical Approach for Low-Risk DTC
• Radioactive Iodine (RAI) Treatment: New Evidence and Changing Indications
• Treatment of Locally Advanced, Metastatic, and RAI-Refractory DTC
• Clinical Implications: What These Findings Mean for Patients
• Limitations of the Current Evidence
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Many small, low-risk thyroid cancers may not need aggressive treatment; active surveillance or lobectomy are alternatives.
• NIFTP reclassifies 10–20% of previously diagnosed thyroid cancers as non-cancerous, reducing unnecessary treatment.
• Low-dose radioactive iodine (1.1 GBq) is as effective as high-dose (3.7 GBq) for low-risk patients in trials.
• Molecular testing or FDG-PET can help avoid unnecessary diagnostic surgery for indeterminate thyroid nodules.
• For RAI-refractory advanced disease, new local treatments like thermal ablation can reduce tumor volume and relieve symptoms.

Background: Why This Research Matters

The last few decades have brought a paradox in thyroid cancer care: more people are being diagnosed with thyroid cancer than ever before, yet the number of people dying from it has not changed. This discrepancy has prompted doctors worldwide to rethink how thyroid cancer should be diagnosed and treated.

The explanation for this paradox lies largely in how the disease is detected. With the widespread use of neck ultrasonography (US) and fine needle aspiration (FNA) — procedures that look inside the thyroid gland — doctors are now finding numerous small, clinically indolent (slow-growing, harmless) tumors that would likely never have caused symptoms or harm. In fact, the increased incidence is almost entirely due to more cases of papillary thyroid carcinoma (PTC), the most common type, and has not been associated with any increase in DTC-related mortality.

This awareness has led to a critical reappraisal of DTC management. The focus has shifted away from treating every tumor aggressively and toward achieving two goals at once: reducing unnecessary burden for patients with very low-risk disease, while correctly identifying those who genuinely need more intensive treatment and follow-up. Recent international guidelines from the American Thyroid Association (ATA) and the European Society of Medical Oncology (ESMO) reflect this more individualized, risk-based approach.

What Is Differentiated Thyroid Carcinoma?

Differentiated thyroid carcinomas arise from the thyroid follicular cells — the cells in your thyroid gland that produce thyroid hormone. They are the most prevalent malignant (cancerous) tumors of the endocrine system, which is the network of hormone-producing glands in the body.

The three most common variants of DTC are:

• Papillary thyroid carcinoma (PTC) — the most common form
• Follicular thyroid carcinoma (FTC)
• Hürthle cell carcinoma (HTC) — a less common variant

Together, these three types represent more than 90% of all thyroid cancers.

Several risk factors are strongly associated with developing DTC:

• A history of DTC in a first-degree relative (parent, sibling, or child)
• Exposure to radiation during childhood
• Rare genetic syndromes that predispose to cancer

The incidence of DTC has increased worldwide over the last decades, with a striking gender difference: the incidence in women is 2.5 to 3 times higher than in men. This increased incidence has been attributed mostly to more widespread use of diagnostic tools like neck ultrasound and FNA, leading to detection of many clinically indolent cases that might otherwise have gone unnoticed.

Encouragingly, increased awareness about potential over-diagnosis has led to a stabilization of DTC incidence in the most recent years. Experts believe this is the result of changes in clinical practice, including less frequent use of ultrasound and more restrictive practices concerning FNA, as recommended by the most recent international guidelines.

How DTC Is Diagnosed: Modern Approaches

Diagnosis and staging of DTC is carried out using a combination of radiologic (imaging-based) and pathologic (tissue-based) methods. The standard diagnostic steps typically follow a structured pathway when a patient presents with a thyroid nodule (a lump in the thyroid gland).

The Role of Fine Needle Aspiration (FNA)

FNA with cytological examination — using a thin needle to withdraw cells from a nodule for microscopic analysis — remains the single most important diagnostic tool to detect or exclude DTC in patients presenting with thyroid nodules. During FNA, a doctor uses a very thin needle to collect a small sample of cells from the thyroid nodule, which are then examined under a microscope.

Selection of patients who undergo FNA should be based on clinical features and ultrasound nodule characteristics. Most recent international guidelines recommend restricting FNA to patients with nodules larger than 1 centimeter (about 0.4 inches), unless there is high clinical or ultrasound suspicion of malignancy. This includes thyroid nodules showing focal (localized) uptake on FDG-PET scans (a specialized imaging test that shows areas of high metabolic activity), which have been shown to be associated with a higher risk of malignancy.

Given that most papillary thyroid microcarcinomas (PTMC — tumors smaller than 1 cm) that are limited to the thyroid carry a very low risk of becoming clinically overt (causing symptoms), the decision to perform FNA in nodules under 1 cm should strongly consider the patient's overall clinical context and carefully balance the potential risks and benefits of subsequent procedures. For these tiny tumors, active surveillance (monitoring the tumor over time rather than treating it immediately) is the recommended option.

Ultrasound Risk Classification: The TIRADS Systems

Diagnostic neck ultrasound should be performed in all patients with a suspicion of a thyroid nodule. It is required to describe the characteristics of the thyroid nodule(s) and to assess the cervical (neck) lymph nodes for signs of cancer spread.

To categorize thyroid nodules by malignancy risk and to adequately select patients who require FNA, Kwak and colleagues developed the Thyroid Imaging Reporting and Data System (TIRADS) criteria in 2011, based on the sonographic (ultrasound) features of thyroid nodules. This system is endorsed by the American College of Radiology (ACR). Other medical societies — including the ATA, the European Thyroid Association (ETA), and the Korean Society of Thyroid Radiology (KSThR) — have proposed different criteria for the same purpose, resulting in EU-TIRADS and K-TIRADS classifications.

Recently, a meta-analysis (a study that combines the results of multiple studies) of comparative studies on these different criteria concluded that, when compared head-to-head, the ACR-TIRADS had a significantly higher diagnostic odds ratio — meaning better overall diagnostic performance — than the ATA or K-TIRADS criteria. An accurate comparison with EU-TIRADS could not be performed because only a small number of studies using EU-TIRADS were included. The meta-analysis mostly included retrospective cohort studies, and more prospective studies are needed to conclude which criteria are truly superior in selecting thyroid nodules that require FNA.

Here is what the different ultrasound classification systems look like in practical terms:

ACR-TIRADS assigns points based on composition, echogenicity (how the nodule appears on ultrasound), shape, margin, and echogenic foci (tiny bright spots):

• 0 points: malignancy risk less than 2% — no FNA recommended
• 2 points: malignancy risk less than 2% — no FNA recommended
• 3 points: malignancy risk 5% — FNA recommended for nodules 2.5 cm or larger
• 4–6 points: malignancy risk 5–20% — FNA recommended for nodules 1.5 cm or larger
• 7 or more points: malignancy risk greater than 20% — FNA recommended for nodules 1 cm or larger

EU-TIRADS categories include:

• No nodule: risk 0%
• Pure cyst or entirely spongiform (honeycomb appearance): risk 0% — no FNA unless compressive symptoms
• Oval, smooth, isoechoic/hyperechoic (similar or brighter appearance than surrounding tissue): risk 2–4% — FNA for nodules over 2 cm
• Oval, smooth, mildly hypoechoic (darker appearance): risk 6–17% — FNA for nodules over 1.5 cm
• At least one feature of high suspicion (irregular shape, irregular margins, microcalcifications, marked hypo-echogenicity): risk 26–87% — FNA for nodules over 1 cm

K-TIRADS categories include:

• No nodule: risk 0%
• Spongiform or partially cystic nodule with comet-tail artifact or pure cyst: risk less than 3% — no FNA
• Partially cystic or isohyperechoic nodule without any of 3 suspicious features (microcalcification, nonparallel orientation, spiculated or microlobulated margin): risk 3–15% — FNA for nodules 1.5 cm or larger
• Solid hypoechoic nodule without suspicious features, or partially cystic/isoechoic nodule with any suspicious feature: risk 15–50% — FNA for nodules 1 cm or larger
• Solid hypoechoic nodule with any of the 3 suspicious features: risk greater than 60% — FNA for nodules 1 cm or larger

ATA classification (categories are named rather than numbered):

• Benign: risk less than 1% — no FNA
• Very low suspicion (spongiform or partially cystic without any sonographic features described in low, intermediate, or high suspicion): risk less than 3% — consider FNA at 2 cm or larger
• Low suspicion (isoechoic or hyperechoic solid or partially cystic nodule without microcalcification, irregular margin, or extrathyroidal extension, or taller-than-wide shape): risk 5–10% — recommend FNA at 1.5 cm or larger
• Intermediate suspicion (hypoechoic solid nodule with smooth margins without microcalcifications, extrathyroidal extension, or taller-than-wide shape): risk 10–20% — recommend FNA at 1.5 cm or larger
• High suspicion (solid hypoechoic nodule or solid hypoechoic component of a partially cystic nodule with irregular margins, microcalcifications, taller-than-wide shape, rim calcifications with small extrusive soft tissue component, and/or extrathyroidal extension): risk greater than 70–90% — recommend FNA at 1 cm or larger

Understanding FNA Results: The Bethesda System

The FNA result is expressed as one of six Bethesda categories, a standardized reporting system that helps doctors communicate cytology findings consistently. While Bethesda categories 2 and 6 can accurately identify benign and malignant nodules respectively, categories 3, 4, and 5 have large interobserver variability — meaning different pathologists may interpret the same sample differently — and cannot reliably distinguish between malignant and benign nodules.

This uncertainty is significant because many patients with nodules in these indeterminate categories undergo diagnostic lobectomy (surgical removal of one thyroid lobe) to rule out malignancy. Particularly for those with Bethesda 3 and 4 categories, which carry an estimated risk of malignancy up to 30%, many of these surgeries could be unnecessary.

Molecular Testing and FDG-PET: Reducing Unnecessary Surgeries

To reduce the number of diagnostic surgeries for nodules in the indeterminate Bethesda categories, several diagnostic advancements have been proposed:

Molecular testing — Tests based on DNA or RNA technologies, either limited to diagnostic mutational panels (which look for specific known cancer-causing gene mutations) or a gene expression classifier (which analyzes the activity of many genes to predict whether a nodule is benign or malignant). These tests have been developed to refine diagnostic accuracy in the Bethesda 3 and 4 categories, with reported sensitivity (correctly identifying cancer when present) of about 90% for most tests, and specificity (correctly identifying benign when benign) between 49% and 92%. While the reported negative predictive value — the probability that a patient truly does not have cancer when the test is negative — is about 95% for most of them, making them suitable as rule-out tests, the positive predictive value — the probability that a patient truly has cancer when the test is positive — varies widely between 37% and 82%.

FDG-PET imaging — A systematic review and meta-analysis by Vriens and colleagues indicates that the lack of FDG-PET uptake in nodules larger than 15 mm with indeterminate cytology excludes malignancy with a 100% sensitivity in those nodules. Furthermore, a recent randomized controlled trial indicates that an FDG-PET/CT-based diagnostic approach toward indeterminate nodules can reduce up to 40% of unnecessary diagnostic surgeries, provided that the nodules are not Hürthle cell neoplasia, which often show increased FDG-PET uptake even when benign.

Used in conjunction with clinical evaluation and other available tools, these techniques have the potential to improve the preoperative diagnostic accuracy of thyroid nodules. Future studies are warranted to establish the most clinically and cost-effective approach algorithm to optimize the diagnostic pathway.

The NIFTP Reclassification: Removing "Cancer" From Select Diagnoses

In another effort to reduce the burden of DTC diagnosis and treatment, Nikiforov and colleagues introduced the term non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) to replace the encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), estimated to represent 10–20% of all DTC diagnosed in Europe and North America.

The motivation behind this reclassification is profound: by removing the word "cancer" from this diagnosis, the goal was to promote a more conservative treatment strategy for NIFTP, with a lesser burden to the patient. This reflects a growing recognition that not all abnormal growths labeled as cancer behave like cancer.

NIFTPs show a rather indolent (slow-growing, harmless) behavior. Several studies on clinical outcomes of patients with NIFTP have shown total absence of lymph node or distant metastases during follow-up. Other studies showed low rates of microscopic (smaller than 2 mm) lymph node metastases, ranging from 2% to 5%. However, some of these tumors showed features characteristic of classic PTC, and not all tumors were entirely sampled (examined). Therefore, the diagnostic criteria of NIFTP were updated in 2018 and now exclude tumors with well-formed papillae (finger-like projections).

Additionally, the absence of mutations typical for PTC — specifically BRAFV600E, TERT, and TP53 mutations — was added as a secondary criterion, and examination of the entire tumor became mandatory. Genetic events that are more commonly detected in FTC, such as RAS mutations or PAX8/PPARg rearrangements, cannot distinguish between follicular carcinoma and adenoma (including Hürthle cell variants) and have not been included in the diagnostic criteria.

For patients, this reclassification means that some individuals who would previously have been told they had thyroid cancer and received aggressive treatment are now diagnosed with a non-cancer condition that can be managed more conservatively, with less surgery, less radioactive iodine, and less psychological burden.

Initial and Ongoing Staging: Predicting Risk and Tailoring Care

In DTC, different staging systems serve different purposes:

The tumor, node, metastasis (TNM) classification system is optimized to predict mortality (death) from DTC. It classifies the tumor based on its size and extent (T), whether it has spread to lymph nodes (N), and whether it has spread to distant organs (M).

The risk stratification proposed by the ATA and ESMO guidelines predicts recurrence (the cancer coming back), which is a more relevant outcome measure in DTC because most patients survive their disease and the main concern is recurrence.

These staging systems can be used as guidance for initial treatment strategies. But importantly, risk stratification should not stop at the time of diagnosis — it should continue during follow-up.

This ongoing stratification system was first described by Tuttle and colleagues and later modified by Vaisman and colleagues. It is based on response to therapy, on which patients should be stratified during their follow-up into four categories:

1. Excellent response — no evidence of disease anywhere
2. Biochemical incomplete response — abnormal blood markers (like thyroglobulin levels) but no visible disease on imaging
3. Structural incomplete response — visible evidence that the disease has returned or persisted
4. Indeterminate response — findings that are not clearly normal or clearly abnormal

This stratification system can predict both recurrence and mortality, has been validated by several studies, and can guide the intensity of follow-up — meaning follow-up can be relaxed for those responding excellently and intensified for those with incomplete responses.

On the molecular front, tumors bearing pathologic BRAF mutations — particularly in combination with TERT mutations — have been associated with unfavorable outcomes. However, although molecular testing is expected to contribute in the future to prognostic assessment, at the moment the way it can be practically used for this purpose has not yet been robustly established.

Treatment Strategies: From Surgery to Radioactive Iodine

The treatment strategy for DTC patients mostly consists of a combination of three approaches:

1. Surgery — removing part or all of the thyroid gland
2. Radioactive iodine (RAI) administration — using radioactive iodine to destroy remaining thyroid tissue or cancer cells
3. Thyrotropin (TSH) suppression therapy — using thyroid hormone medication to keep TSH levels low, which can slow the growth of any remaining thyroid cancer cells

The extent of the different treatment modalities depends on initial and ongoing risk stratification. Recent developments have questioned some traditional treatment strategies, particularly with respect to low-risk DTC, while other treatment modalities have been introduced.

A Less Extensive Surgical Approach for Low-Risk DTC

Total thyroidectomy (removal of the entire thyroid gland) has been the standard surgical procedure for the management of DTC. For patients with intermediate- and high-risk DTC, total thyroidectomy with the addition of neck lymph node dissection — in cases where there is clinical or ultrasound evidence of lymph node metastases — remains the recommended initial surgical approach.

However, several large retrospective studies have shown that in low-risk papillary thyroid microcarcinoma (PTMC) and in carefully selected low-risk DTC patients, unilateral lobectomy (removing only the thyroid lobe containing the tumor) can be an alternative without reducing survival rates or increasing the risk of recurrence. Because unilateral lobectomy is associated with lower complication rates and lower costs, large multicenter prospective randomized controlled trials to validate these findings would be very valuable. Nonetheless, given the high long-term survival and low prevalence of recurrences associated with these tumors, a well-powered prospective randomized study requires very large patient groups and lengthy follow-up — which are likely only feasible based on non-inferiority endpoints (proving the less extensive treatment is not worse than the standard one).

Moreover, uniform protocols need to be established for the intensity and duration of follow-up in patients with low-risk DTC who undergo lobectomy as primary treatment.

For patients with low-risk PTMC, defined as unifocal (single) tumors limited to the thyroid, without extrathyroidal extension (spread beyond the thyroid), without clinical or ultrasound evidence of lymph node or distant metastases, and without other risk factors such as worrisome pathological features (e.g., tall cell, insular, or columnar cell variants) or molecular features (e.g., combination of pathological BRAF and TERT mutations), unilateral lobectomy is the recommended treatment.

Minimally Invasive Techniques (MIT) and Active Surveillance

Moving even further away from aggressive surgery, several studies summarized in recent systematic reviews and meta-analyses indicate that patients with low-risk PTMC are eligible for image-guided minimally invasive techniques (MIT), particularly thermal ablation — using heat to destroy the tumor. The main thermal ablation methods include:

• Laser ablation (LA)
• Radiofrequency ablation (RFA)
• Microwave ablation (MWA)

These techniques achieve comparable results to surgery with respect to local disease control and have low complication rates. Therefore, in centers where expertise is available, MIT can be offered as an alternative to surgery in patients with incidentally discovered low-risk PTMC who are not eligible for surgery or who decline it.

The European Thyroid Association (ETA) and the Cardiovascular and Interventional Radiological Society of Europe have recently published a guideline on application of MIT in thyroid carcinoma. This document describes the techniques that are suitable for different indications and details the characteristics of patients who could be eligible for MIT.

Furthermore, accumulating evidence indicates that active surveillance (carefully monitoring the tumor without immediate treatment) can provide a safe option in selected patients with low-risk PTMC who are not eligible for surgery or who decline it.

Currently, no studies are available providing head-to-head comparison of these treatment modalities (surgery, MIT, and active surveillance) for PTMC, and there is still limited long-term data available on the outcome of patients treated by MIT or undergoing active surveillance, particularly in populations of European descent. Nonetheless, as these approaches are being increasingly used in Europe and the USA, it is expected that more studies will accumulate knowledge on the safety and long-term outcome of these procedures and their potential to improve long-term quality of life for patients with DTC.

Importantly, broader implementation of shared decision-making should enable better participation of patients in decisions about their management. Shared decision-making can help improve communication with physicians, provide better empowerment and satisfaction — leading to decisions that better match patients' preferences and expectations.

Radioactive Iodine (RAI) Treatment: New Evidence and Changing Indications

Given the evidence of improved prognosis of patients with DTC after the introduction of RAI treatment following surgery, RAI treatment has been recommended for many years for the large majority of DTC patients. In the past decade, however, the place of RAI in the treatment armamentarium for DTC was reappraised, considering the more individualized, risk assessment-based approach.

In patients with DTC, RAI can be administered for several indications:

• Remnant ablation — destroying normal thyroid tissue remnant after surgery, which renders follow-up of thyroglobulin levels (a blood marker for thyroid tissue or cancer) sensitive for DTC recurrence
• Adjuvant setting — destroying presumed microscopic foci of DTC, thus reducing recurrence risk
• Treatment of persistent or recurrent disease

The additive value of post-surgical RAI treatment should be based on individual prognostic factors regarding risk of cancer-related death or disease recurrence. For this, the aforementioned risk stratification is paramount. While it is widely agreed that post-surgical RAI treatment is indicated in high-risk DTC patients, there is less consensus regarding the indications in intermediate- and low-risk patients.

Intermediate-Risk Patients

In intermediate-risk patients, individual risk factors should be considered when estimating the benefits of RAI treatment. A systematic review by Sacks and colleagues concluded that survival was improved in DTC patients older than 45 years with TNM stage III who received RAI treatment compared to patients who did not. The benefit in patients younger than 45 years was unclear.

The recent ETA consensus statement indicates that the following factors have been associated with the greatest benefit of adjuvant RAI treatment:

• Advanced age
• Aggressive histology (tumor appearance under the microscope)
• Large volume of nodal disease
• Extranodal extension (spread of cancer beyond the lymph node capsule)
• Multiple N1 (lymph node positive) and/or lymph node metastases outside the central neck

More prospective studies are needed to further elucidate the individual factors associated with benefit from RAI treatment in intermediate-risk DTC patients.

Low-Risk Patients: Landmark Trial Results

The benefit of post-surgical RAI treatment in low-risk patients is, in light of emerging evidence, highly debated. As shown by a systematic review by Verbrug and colleagues including 11 retrospective cohort studies, results are not consistent.

Recently, a landmark randomized controlled trial by Leboulleux and colleagues showed that in patients with low-risk DTC undergoing thyroidectomy, a follow-up strategy without RAI remnant ablation was non-inferior (not worse) to a follow-up strategy including RAI remnant ablation. The primary endpoint was the percentage of patients without an event during 3 years after randomization. This event was a composite endpoint of functional, structural, and biologic criteria. More studies are needed to validate these findings, particularly to assess long-term outcomes. Until then, the indication for RAI treatment in low-risk DTC patients should be based on individual prognostic risk factors.

Regarding the RAI activity (dose) required in low-risk DTC patients, two large randomized controlled trials have compared high-dose post-operative RAI ablation (3.7 GBq) with low-dose (1.1 GBq):

The ESTIMABL1 trial was conducted in 24 centers in France between 2007 and 2010. It included 752 low-risk DTC patients, randomized between four treatment strategies: low or high dose RAI ablation combined with TSH stimulation using either recombinant human TSH (rhTSH — a synthetic form of TSH given by injection) or thyroid hormone withdrawal (stopping thyroid hormone medication to raise natural TSH levels). After a median follow-up of 5.4 years, no differences in recurrence rates were found between the different treatment strategies.

The HiLo trial took place in 29 centers in the United Kingdom, also between 2007 and 2010. In this study, 438 patients were randomized between the same treatment strategies as the ESTIMABL1 trial. The results showed no significant differences in recurrence rates between the treatment strategies after a median follow-up of 6.5 years.

Based on this data, it is currently recommended that, if post-surgical remnant ablation is prescribed in low-risk patients, this can take place using 1.1 GBq of 131I (low-dose) preceded by rhTSH. This approach reduces the amount of radioactivity administered and the discomfort caused by thyroid hormone withdrawal — which can cause symptoms of hypothyroidism (fatigue, weight gain, depression) for several weeks.

Treatment of Locally Advanced, Metastatic, and RAI-Refractory DTC

Most DTC patients have an excellent prognosis, with a 10-year survival around 90%. Nonetheless, a minority develops recurrent or metastatic (spread to distant organs) disease, and of these, approximately 40% become resistant to conventional treatment — meaning their tumors no longer take up radioactive iodine.

The overall survival for patients with advanced or metastatic DTC resistant to RAI therapy is poor, with 5-year survival rates of 50% and 10-year survival rates of 10%. Treatment options for these patients are limited and rarely result in cure of the disease. Nevertheless, during the last decades, new treatment modalities have been introduced that have improved progression-free survival (PFS) — the length of time during and after treatment that a patient lives with the disease without it getting worse. These include both local and systemic treatments.

Local Treatment Options

In case of recurrent disease, surgical removal of metastases and/or RAI treatment (as long as the tumor has not become refractory) are the preferred treatment modalities. For patients with RAI-refractory DTC that are not amenable to surgery — such as patients in poor condition, patients declining surgery, or patients with unresectable (cannot be surgically removed) disease — other local treatment options are available, such as external beam radiotherapy (radiation delivered from outside the body) and, more recently introduced, image-guided minimally invasive techniques (MIT).

In unresectable DTC, MIT may be used for symptomatic tumor volume reduction. Two case series of unresectable local recurrent DTC treated with radiofrequency ablation (RFA) showed volume reduction rates of 51% and 81%.

MIT can also be used for reduction of symptoms caused by distant metastases. DTC most commonly metastasizes to the lungs and bones. A recent retrospective multicenter study investigated the efficacy and safety of MIT (RFA, microwave ablation, and cryoablation — freezing the tumor) in pulmonary (lung) DTC metastases. After a median follow-up of 5.2 years, local tumor progression was observed in 4 of 34 DTC patients, and no major complications occurred.

Two prospective multicenter trials studied the efficacy of RFA and cryoablation in 55 and 61 patients, respectively, with symptomatic bone metastases — including DTC patients as part of a broader group. These studies help establish MIT as a viable option for reducing pain and local symptoms from bone metastases.

Clinical Implications: What These Findings Mean for Patients

This review represents a fundamental shift in how thyroid cancer is perceived and managed, with several direct implications for patients:

First, not every thyroid cancer needs aggressive treatment. Many small, low-risk tumors can be safely managed with active surveillance, lobectomy rather than total thyroidectomy, or minimally invasive thermal ablation — all of which carry fewer side effects and less impact on quality of life than traditional approaches.

Second, the diagnosis itself is being refined. With the introduction of NIFTP — which affects 10–20% of what was previously diagnosed as thyroid cancer in Europe and North America — some patients are now spared the diagnosis of cancer entirely, along with the psychological burden and aggressive treatment that comes with it.

Third, RAI treatment is no longer automatic. The evidence from the ESTIMABL1 and HiLo trials shows that for low-risk patients, low-dose RAI (1.1 GBq) is as effective as high-dose (3.7 GBq), and — following the Leboulleux trial — some low-risk patients may not need RAI at all. This means less radiation exposure, fewer side effects, and less disruption to daily life from thyroid hormone withdrawal.

Fourth, advanced disease is no longer hopeless. Although RAI-refractory DTC has historically had poor outcomes — with 5-year survival of 50% and 10-year survival of 10% — newer local treatments like thermal ablation for lung and bone metastases, along with systemic therapies, are improving progression-free survival. For patients with unresectable local recurrences, RFA has shown tumor volume reduction rates of 51–81%, offering meaningful symptom relief.

Fifth, shared decision-making is essential. Given the growing number of valid treatment options — surgery, MIT, active surveillance — with comparable outcomes for low-risk disease, patients should be active participants in choosing their care path. The authors emphasize that shared decision-making improves communication, patient empowerment, and satisfaction.

Limitations of the Current Evidence

While this review presents robust evidence for the changing landscape of DTC management, several limitations should be acknowledged:

• The meta-analysis comparing TIRADS classification systems mostly included retrospective cohort studies, which are more prone to bias than prospective studies. Only a small number of studies using EU-TIRADS were available, preventing an accurate comparison of EU-TIRADS performance.
• Molecular testing in indeterminate thyroid nodules shows variable positive predictive values (37–82%), meaning a positive test does not always confirm cancer, and the most clinically and cost-effective testing algorithm has not yet been established.
• Regarding MIT and active surveillance for low-risk PTMC, no head-to-head comparison studies exist, and long-term outcome data are limited — particularly in European-derived populations.
• For the recommendation of lobectomy over total thyroidectomy in low-risk disease, the supporting evidence comes largely from large retrospective studies rather than prospective randomized trials. The authors note that well-powered prospective randomized studies are very difficult to conduct because of the high survival rates and long follow-up required.
• The evidence for omitting RAI in low-risk patients is based primarily on the single randomized trial by Leboulleux and colleagues with 3-year follow-up; longer-term outcomes are still needed.
• In intermediate-risk patients, the factors associated with RAI benefit have been identified largely from retrospective analyses and expert consensus, with more prospective studies needed.
• While molecular markers like BRAF and TERT mutations are known to be associated with unfavorable outcomes, the practical integration of molecular testing into routine prognostic assessment has not yet been robustly established.

Recommendations for Patients

Based on this update, patients and their families may find the following points useful when discussing care with their medical team:

1. Ask about active surveillance for small tumors. If you have a papillary thyroid microcarcinoma (under 1 cm) confined to the thyroid, active surveillance may be a safe option. Ask your doctor about the risks and benefits of monitoring versus immediate treatment.
2. Explore all surgical options. If you have low-risk DTC, ask whether unilateral lobectomy (removing only the affected lobe) might be appropriate rather than total thyroidectomy. This can mean a lower risk of complications and potentially no need for lifelong thyroid hormone replacement.
3. Ask about minimally invasive techniques (MIT). For low-risk microcarcinomas, thermal ablation (laser, radiofrequency, or microwave) may be an option if you are not eligible for surgery or prefer to avoid it. These procedures are performed at specialized centers with appropriate expertise.
4. If you have indeterminate results on FNA (Bethesda 3 or 4), ask about additional testing. Molecular testing (with roughly 90% sensitivity) or FDG-PET imaging (for nodules over 15 mm) may help you avoid an unnecessary diagnostic surgery.
5. Ask about RAI dosing. If RAI treatment is recommended for low-risk disease, ask whether the low-dose regimen (1.1 GBq) with rhTSH stimulation is appropriate rather than high-dose RAI with thyroid hormone withdrawal. Ask whether RAI is needed at all based on your individual risk factors.
6. Request ongoing risk stratification during follow-up. Your treatment plan should be re-evaluated over time based on your response to therapy (excellent, biochemical incomplete, structural incomplete, or indeterminate). This determines whether follow-up intensity can be reduced or should be increased.
7. Participate in shared decision-making. Ask your medical team to explain the trade-offs between treatment options, including side effects, quality-of-life impacts, and long-term outcomes. The best decision is one that aligns with your values, preferences, and expectations.
8. For advanced or RAI-refractory disease, ask about local treatment options. Image-guided minimally invasive techniques can reduce tumor volume and relieve symptoms from unresectable recurrences or lung and bone metastases, with low complication rates based on recent studies.

Frequently Asked Questions

I was just told I have a small thyroid cancer under 1 cm. Do I need surgery right away?

For a papillary thyroid microcarcinoma confined to the thyroid, active surveillance—careful monitoring without immediate treatment—may be a safe option. This is recommended when there are no worrisome features. Ask your doctor whether monitoring versus immediate surgery is appropriate for your specific situation.

My thyroid nodule biopsy came back as indeterminate (Bethesda 3 or 4). Can I avoid surgery?

Yes, additional tests may help. Molecular testing has about 90% sensitivity for detecting cancer, and a negative result means a roughly 95% chance it is benign. FDG-PET scanning for nodules larger than 15 mm can also help—a lack of uptake may rule out cancer. These tests may reduce unnecessary diagnostic surgeries.

What is NIFTP and does it mean I don't have cancer?

NIFTP stands for non-invasive follicular thyroid neoplasm with papillary-like nuclear features. It was introduced to replace a previously diagnosed form of thyroid cancer. Tumors meeting strict criteria are now considered non-cancerous. This means some patients can avoid aggressive treatment and the psychological burden of a cancer diagnosis.

I have low-risk thyroid cancer. Can I have just a lobectomy instead of removing the whole thyroid?

For carefully selected low-risk patients, unilateral lobectomy—removing only the lobe containing the tumor—can be an alternative to total thyroidectomy. Studies suggest it does not reduce survival or increase recurrence risk for these patients. Lobectomy also has fewer complications and may avoid lifelong thyroid hormone replacement.

I was told I need radioactive iodine treatment. Is the full dose always necessary?

No. For low-risk patients, two large trials found that low-dose radioactive iodine (1.1 GBq) was as effective as high-dose (3.7 GBq) in preventing recurrence. Another study showed that for some low-risk patients, no radioactive iodine at all was not worse than receiving it. Always discuss your individual risk factors.

What does it mean if my thyroid cancer is called RAI-refractory?

RAI-refractory means the cancer no longer takes up radioactive iodine, so that treatment is no longer helpful. Historically, survival was poor, but newer local and systemic treatments are improving progression-free survival. For example, thermal ablation can shrink unresectable recurrences and metastases, providing symptom relief with low complication rates.

How will my doctor know if my treatment is working during follow-up?

You will be regularly re-evaluated and placed into one of four response categories: excellent (no evidence of disease), biochemical incomplete (abnormal blood markers but no visible disease), structural incomplete (visible disease), or indeterminate (unclear findings). This ongoing risk stratification guides whether follow-up can be relaxed or needs to be more intensive.

Source Information

Original Article Title: Differentiated thyroid carcinoma- An update

Journal: Best Practice & Research Clinical Endocrinology & Metabolism, Volume 37, 2023, Article 101687. Available online 12 August 2022. Published by Elsevier Ltd.

DOI: https://doi.org/10.1016/j.beem.2022.101687

This patient-friendly article is based on peer-reviewed research. The original article is an open-access publication under the CC BY-NC-ND license (creativecommons.org/licenses/by-nc-nd/4.0/).

Note: This content is intended for educational purposes and should not replace professional medical advice. Always discuss your individual situation with your healthcare provider.